Injectafer denied as experimental or investigational by Humana?

Humana's specific coverage criteria for injectafer are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Injectafer as Experimental

An experimental or investigational denial means Humana's medical policy team determined that the evidence supporting Injectafer (ferric carboxymaltose) for the specific indication your prescriber documented does not yet meet the plan's coverage threshold for established clinical benefit. This sometimes happens when Injectafer is prescribed for an indication that, while recognized clinically, may be characterized as emerging in Humana's internal coverage criteria.

This denial is strongly appealable. Injectafer holds full FDA approval for defined indications listed in its prescribing label. An "experimental" classification applied to an FDA-approved drug used on-label — or to an off-label use with substantial guideline support — is a factual claim Humana must be able to defend at external review.

## Federal Appeal Framework

Under ACA §2719, non-grandfathered plans must offer external review by an accredited Independent Review Organization (IRO) after an internal appeal is exhausted. ERISA §503 gives employer-plan participants the right to review the clinical evidence and criteria supporting the denial. The external-review window is typically four months from the denial notice. An expedited review option exists for urgent situations and must be resolved within 72 hours of request.

## Concrete Appeal Steps

1. Obtain the exact policy language and evidence review Humana used to classify this use as experimental. 2. Confirm in writing with your prescriber whether the prescribed use is on-label or off-label; if off-label, identify which major clinical guideline organization (such as NCCN, ADA, ASH, or the applicable specialty society) endorses the use. 3. Submit your internal appeal with supporting documentation to Humana's appeals unit within the stated deadline. 4. Request peer-to-peer review between your prescriber and Humana's medical director — this is an underused step that can resolve experimental denials before external review. 5. If the internal appeal is denied, proceed immediately to external review.

## Documentation to Gather

• Diagnosis confirmation: Physician chart notes and diagnostic workup establishing the condition.
• Prescriber justification letter: Cites the FDA-approved label and, if applicable, the relevant guideline organization endorsing this use.
• Prior-treatment history: Alternatives tried, with dates and documented outcomes, showing the clinical pathway that led to Injectafer.
• Clinical severity: Objective chart documentation of severity and functional impact.

## Criteria-Mapping Structure

Pull the Injectafer FDA prescribing label and Humana's published investigational/experimental coverage policy. Build a response table:

| Humana experimental-review criterion | Supporting evidence | |---|---| | FDA approval status for this indication | [On-label: cite label section; or off-label with guideline citation] | | Established clinical benefit per plan evidence standard | [Prescriber letter + applicable guideline organization] | | No adequate alternative covered therapy | [Prior-treatment history with outcomes] |

Address each criterion Humana listed in the denial notice. An IRO reviewing this denial will assess the same evidence and is not bound by Humana's internal policy.